Mustang Bio, Inc. (MBIO) Stock Price & Analysis
Mustang Bio, Inc. (MBIO) fell 1.42% to USD 0.56 as of July 25, 2026 at 06:51 UTC, according to Nexqual real-time market data.
MBIO last closed at USD 0.57; the session ranged USD 0.56–0.59 on volume of 16,210 shares. Market capitalization is $4.26M, with a 52-week range of USD 0.53–2.09 (NCM). Source: Nexqual, July 25, 2026 at 06:51 UTC.
Key Statistics (as of July 25, 2026 at 06:51 UTC)
| Price | USD 0.56 |
|---|---|
| Change | ▼ 1.42% (down) |
| Previous Close | USD 0.57 |
| Open | USD 0.59 |
| Day Range | USD 0.56 – 0.59 |
| 52-Week Range | USD 0.53 – 2.09 |
| Volume | 16,210 shares |
| Market Cap | $4.26M |
| Exchange | NCM |
Technical Analysis (MBIO)
Nexqual's technical model rates MBIO "SELL" based on 2 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 06:51 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 35.38 (neutral) |
| vs SMA50 | Below (USD 0.67) |
| MACD | -0.03 (negative) |
Analyst Ratings (MBIO)
Wall Street analysts rate MBIO "None", per Nexqual as of July 25, 2026 at 06:51 UTC.
| Consensus Rating | None |
|---|
Earnings (MBIO)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2024-12-31 | USD 3.63 vs est -8 ▲ beat |
| 2024-09-30 | USD -2 vs est -6.5 ▲ beat |
| 2024-06-30 | USD -12 vs est -7 ▼ miss |
| 2024-03-31 | USD -23 vs est -11 ▼ miss |
Source: Nexqual, July 25, 2026 at 06:51 UTC.
Financials & Fundamentals (MBIO)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -44.62% |
| Current Ratio | 2.12 |
| Total Cash | $16.26M |
| Total Debt | $0 |
| Free Cash Flow | $-4.87M |
Source: Nexqual, July 25, 2026 at 06:51 UTC.
Financial Health Score (MBIO)
Nexqual rates Mustang Bio, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 06:51 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $16M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$5M |
| Efficiency | Critical — ROE -45%, ROA -12.8% |
Ownership (MBIO)
| Insider Ownership | +8.02% |
|---|---|
| Institutional Ownership | +9.47% |
| Shares Outstanding | 6.73M |
| Float | 5.35M |
| Short % of Float | +0.90% |
Source: Nexqual, July 25, 2026 at 06:51 UTC.
Leadership (MBIO)
Mustang Bio, Inc. is led by Manuel Litchman (age 71), President, CEO, Interim CFO & Director, per Nexqual as of July 25, 2026 at 06:51 UTC.
| President, CEO, Interim CFO & Director | Manuel Litchman (age 71) |
|---|---|
| Executive Chairman | Michael S. Weiss Esq. (age 59) |
Major Backers & Investors (MBIO)
Notable institutional backers of Mustang Bio, Inc. include Kestra Advisory Services, LLC, Fidelity, Citadel, according to Nexqual as of July 25, 2026 at 06:51 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Kestra Advisory Services, LLC | 2.61% |
| Fidelity | 1.33% |
| Citadel | 0.79% |
| CFO4Life Group, LLC | 0.3% |
| Two Sigma Investments, LP | 0.25% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 1.38% |
| BlackRock | 1.26% |
| Vanguard Group | 1.24% |
Source: Nexqual, July 25, 2026 at 06:51 UTC.
From Mustang Bio, Inc.'s Latest SEC 10-K Filing (filed 2026-03-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States.
- It has a license agreement with city of hope national medical center and nationwide children's hospital.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| FBIO | Fortress Biotech, Inc. | USD 3.34 | ▼ 5.92% |
| NDRA | ENDRA Life Sciences Inc. | USD 4.86 | ▼ 13.37% |
| PTN | Palatin Technologies, Inc. | USD 7.71 | ▼ 5.46% |
| NCNA | NuCana plc | USD 1.29 | ▼ 5.15% |
| DARE | Dare Bioscience, Inc. | USD 1.28 | ▲ 4.92% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:51 UTC. This page is informational and not investment advice.